Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration

被引：0
|
作者：
Luis Javier Hernández-Pastor
Ana Ortega
Alfredo García-Layana
Joaquín Giráldez
机构：
[1] Clínica Universidad de Navarra,Department of Pharmacy
[2] Clínica Universidad de Navarra,Department of Ophthalmology
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2010年 / 248卷
关键词：
Age-related macular degeneration; Ranibizumab; Pegaptanib; Cost-effectiveness; Cost-utility;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：467 / 476
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (04) : 467 - 476
  • [2] Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
    Hurley S.F.
    Matthews J.P.
    Guymer R.H.
    [J]. Cost Effectiveness and Resource Allocation, 6 (1)
  • [3] Cost-Effectiveness of Ranibizumab Compared with Photodynamic Treatment of Neovascular Age-Related Macular Degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    [J]. CLINICAL THERAPEUTICS, 2008, 30 (12) : 2436 - 2451
  • [4] Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
    Takeda, A. L.
    Colquitt, J.
    Clegg, A. J.
    Jones, J.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (09) : 1177 - 1182
  • [5] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Morii, Junko
    Kunikane, Eriko
    Sakamoto, Taiji
    [J]. OPHTHALMOLOGY AND THERAPY, 2023, 12 (04) : 2005 - 2021
  • [6] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yasuo Yanagi
    Kanji Takahashi
    Tomohiro Iida
    Fumi Gomi
    Junko Morii
    Eriko Kunikane
    Taiji Sakamoto
    [J]. Ophthalmology and Therapy, 2023, 12 : 2005 - 2021
  • [7] Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yasuo Yanagi
    Kanji Takahashi
    Tomohiro Iida
    Fumi Gomi
    Junko Morii
    Eriko Kunikane
    Taiji Sakamoto
    [J]. Ophthalmology and Therapy, 2023, 12 : 2821 - 2822
  • [8] Pegaptanib for neovascular age-related macular degeneration
    Gragoudas, ES
    Adamis, AP
    Cunningham, ET
    Feinsod, M
    Guyer, DR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27): : 2805 - 2816
  • [9] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
    Yu, Justin S.
    Carlton, Rashad
    Agashivala, Neetu
    Hassan, Tarek
    Wykoff, Charles C.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752
  • [10] Cost-effectiveness of ranibizumab and bevacizumab for neovascular age-related macular degeneration: 1 year IVAN results
    Rogers, Chris
    Dakin, Helen
    Wordsworth, Sarah
    Abangma, Giselle
    Raftery, James
    Harding, Simon
    Chakravarthy, Usha
    Lotery, Andrew
    Downes, Susan
    Reeves, Barnaby
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
12345